Compugen (NASDAQ:CGEN) Upgraded to Hold by StockNews.com

StockNews.com upgraded shares of Compugen (NASDAQ:CGENGet Rating) from a sell rating to a hold rating in a research note issued to investors on Tuesday morning.

Several other brokerages have also recently issued reports on CGEN. Jefferies Financial Group cut shares of Compugen from a buy rating to a hold rating and set a $2.00 price target for the company. in a research report on Friday, August 5th. JMP Securities decreased their price target on shares of Compugen from $8.00 to $4.00 and set a market outperform rating for the company in a research report on Monday, August 8th. Oppenheimer decreased their price target on shares of Compugen from $14.00 to $12.00 and set an outperform rating for the company in a research report on Monday, August 8th. Finally, Truist Financial decreased their price target on shares of Compugen from $14.00 to $4.00 and set a buy rating for the company in a research report on Tuesday, August 23rd. Two investment analysts have rated the stock with a hold rating and four have given a buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of Moderate Buy and an average price target of $6.20.

Compugen Stock Down 3.8 %

Shares of NASDAQ:CGEN opened at $0.91 on Tuesday. The company’s 50 day moving average price is $1.41 and its two-hundred day moving average price is $2.04. Compugen has a 12-month low of $0.91 and a 12-month high of $7.48. The firm has a market cap of $79.02 million, a PE ratio of -2.34 and a beta of 2.15.

Compugen (NASDAQ:CGENGet Rating) last issued its quarterly earnings results on Thursday, August 4th. The biotechnology company reported ($0.11) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.12) by $0.01. During the same quarter in the prior year, the company posted ($0.11) EPS. On average, research analysts expect that Compugen will post -0.43 EPS for the current year.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the business. Advisor Group Holdings Inc. increased its stake in shares of Compugen by 29.3% in the first quarter. Advisor Group Holdings Inc. now owns 27,241 shares of the biotechnology company’s stock worth $87,000 after purchasing an additional 6,174 shares in the last quarter. Envestnet Asset Management Inc. grew its stake in Compugen by 23.4% in the 1st quarter. Envestnet Asset Management Inc. now owns 33,260 shares of the biotechnology company’s stock worth $111,000 after buying an additional 6,299 shares in the last quarter. XTX Topco Ltd grew its stake in Compugen by 23.7% in the 1st quarter. XTX Topco Ltd now owns 44,918 shares of the biotechnology company’s stock worth $145,000 after buying an additional 8,615 shares in the last quarter. Jane Street Group LLC grew its stake in Compugen by 13.8% in the 2nd quarter. Jane Street Group LLC now owns 74,231 shares of the biotechnology company’s stock worth $137,000 after buying an additional 8,980 shares in the last quarter. Finally, Raymond James & Associates grew its stake in Compugen by 5.4% in the 4th quarter. Raymond James & Associates now owns 213,510 shares of the biotechnology company’s stock worth $918,000 after buying an additional 11,015 shares in the last quarter.

Compugen Company Profile

(Get Rating)

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I clinical study in patients with advanced malignancies as a monotherapy; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with solid tumors; and AZD2936, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase I/II clinical study in patients with advanced or metastatic non-small cell lung cancer.

See Also

Analyst Recommendations for Compugen (NASDAQ:CGEN)

Receive News & Ratings for Compugen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Compugen and related companies with MarketBeat.com's FREE daily email newsletter.